
The Weekly Roundup: August 11-15
Key Takeaways
- Nektar's Rezpegaldesleukin shows promise in treating autoimmune disorders, including alopecia and lupus, potentially revolutionizing therapy approaches.
- Guselkumab demonstrates significant long-term benefits for plaque psoriasis, improving quality of life and reducing stigmatization.
In case you missed it, this week we had news about the first annual GPP Awareness Day, a warning from the FDA on whipped sunscreens, the accuracy of vitiligo video content on TikTok, and more.
To stay up-to-date with the latest dermatology news, sign up to receive our
Explore the latest advancements in psoriasis treatment, including pediatric care and innovative therapies, during Psoriasis Action Month. Stay informed!
Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.
Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.
IKI Skin Care by Maria Urbani, MD offers effective solutions for rosacea and sensitive skin through science-backed, minimalist formulations.
Explore the evolving landscape of moderate psoriasis treatment, emphasizing patient-centered care and innovative therapies for improved quality of life.
New insights reveal that those with low BSA involvement often face significant disease burdens, challenging traditional treatment criteria.
New 76-week data reveals guselkumab's significant benefits for plaque psoriasis, enhancing clinical outcomes, improving quality of life, and reducing stigmatization.
Steven Daveluy, MD, highlighted lack of awareness and early misdiagnosis as major barriers to effective HS care.
This review of the latest dermatologic studies includes findings on cybersecurity practices in dermatology, compression therapy for cellulitis, melanoma overdiagnosis, and more.
Explore personalized systemic therapies for atopic dermatitis, addressing patient needs, treatment options, and enhancing adherence for better outcomes.
Vitiligo significantly influences patients' quality of life, affecting major life decisions and increasing perceived stigma.
Merck's pembrolizumab gains Health Canada approval for innovative perioperative treatment of advanced head and neck squamous cell carcinoma, enhancing patient outcomes.
TikTok's vitiligo content reveals a critical need for reliable clinical information from HCPs, highlighting the gap between engagement and accuracy in health education.
Shannon C. Trotter, DO, FAOCD, FAAD, and patient Janene Tirado, highlight GPP Awareness Day and the urgent need for recognition and understanding of generalized pustular psoriasis.
Explore innovative nonsteroidal treatments for atopic dermatitis, as experts discuss personalized care strategies to enhance patient quality of life.
Discover how the NEA Seal of Acceptance helps clinicians recommend safe eczema products, ensuring quality and sensitivity for patients with atopic dermatitis.
The FDA warned Supergoop and Vacation Inc. for marketing unapproved mousse sunscreens.
Andrade's inspiring journey highlights the challenges of HS and the transformative impact of clinical trials.
Irina Mazur spoke to Dermatology Times about the latest partnership, which aims to bridge the gap between clinical advice and patient behavior through personalized sun protection guidance.
Explore innovative acne therapies, including bimekizumab, offering hope for treatment-resistant acne conglobata and improved patient outcomes.
Explore how synthetic data revolutionizes CSU research, enabling smaller sample sizes and enhancing trial efficiency and inclusivity.
Discover how internet-based therapy effectively treats dermatological BFRBs like trichotillomania and dermatillomania, enhancing patient outcomes and accessibility.
A recent HS Summit hosted by UCB brought together clinicians and patient advocates to strengthen research and awareness efforts.
The latest study reveals the link between cosmetic use and acne, highlighting the risks of comedogenic ingredients in moisturizers, facial cleansers, and powders.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















